

EDITORIAL COMMENTARY

Stiff man syndrome, 40 years later

The stiff man syndrome is a rare disorder of the CNS, which is characterised clinically by fluctuating and progressive muscle rigidity and spasms. It was recognised as a distinct entity in 1956 by Moersch and Woltman.^{1,2} The diagnosis relies also on the presence of continuous motor unit activity, without evidence of neuromyotonia, extrapyramidal or pyramidal dysfunction, or focal lesions of the spinal cord. Rigidity and spasms may dominate in the axial muscles, or in one or more distal limbs at clinical examination.

In 1986, the acute onset of diabetic ketoacidosis in a patient affected by stiff man syndrome, prompted us to investigate further the potential pathogenetic association of the two entities.³⁻⁵ Fifty to sixty per cent of these patients have autoantibodies in the serum and CSF directed against glutamic acid decarboxylase (GAD), an enzyme present in GABA-ergic neurons and pancreatic β -cells and a high proportion of them have other autoimmune diseases including diabetes mellitus.³⁻⁵ Interestingly GAD was found to be a major autoantigen in insulin dependent diabetes mellitus and autoantibodies are markers of a high risk of developing diabetes mellitus.^{6,7} A minority of patients (5%–10%) affected by the stiff man syndrome and cancer (usually women with breast cancer) have autoantibodies directed against the 128 kDa autoantigen identified as amphiphysin I, a protein associated with synaptic vesicles.^{8,9} A considerable proportion of patients (around 40%) affected by this chronic disorder show no signs of autoimmunity and may thus represent a different subgroup of patients.^{2,5,10}

In the paper by Barker *et al* (this volume, pp 633–640), 23 cases of stiff man syndrome studied at a single institution from 1986 are reviewed. On clinical and electrophysiological grounds, the authors have identified three groups of patients:

(1) Progressive encephalomyelitis with rigidity: a very rare rapidly deteriorating condition characterised by widespread rigidity.

(2) Stiff man syndrome: rigidity and spasms of the lumbar paraspinal, abdominal, and occasionally proximal leg muscles. Neurophysiology showed continuous muscle unit activity with abnormal exteroceptive reflexes. They responded to GABA-ergic drugs, remained ambulant, and were almost all anti-GAD positive (7/8).

(3) Stiff limb syndrome: rigidity, painful spasms of a distal limb, usually the leg. About half of the patients went on to develop sphincter or brainstem involvement. Neurophysiology showed continuous muscle unit activity with abnormal exteroceptive reflexes and abnormally segmented EMG activity during spasms. They only partially re-

sponded to GABA-ergic drugs and half became wheelchair bound. Only two of 13 had anti-GAD autoantibodies. However five of 13 had other non-specified autoantibodies in this last group of patients.

Although a significant overall overlap exists between the stiff man syndrome and stiff limb syndrome groups as previously noted by other investigators,^{2,11} the subdivision proposed by Barker *et al* might be of help in the future to better identify GABA-ergic drug resistant patients who might benefit from other treatments. It would be interesting also to study this subgroup of patients for novel potential autoantigens and therapeutic targets.

After a little more than 40 years from its initial identification, who might have thought that stiff man syndrome, a rare neurological disease, could have shed so much light on clinical and basic investigation?

In conclusion, I view stiff man syndrome as a heterogenous disease and studies like the one by Barker *et al* and others to come will help us to better subdivide stiff patients on the basis of clinical and laboratory criteria.

FRANCO FOLLI

Unit for Metabolic Diseases, and Department of Medicine I, IRCCS H S Raffaele, Milano, Italy

Correspondence to: Dr Franco Folli, Unit for Metabolic Diseases and Department of Medicine I, IRCCS H S Raffaele, Via Olgettina, 60 20132 Milano, Italy. Telephone: 0039 2 26432895; fax 0039 2 26433790; email folli.franco@hsr.it

- 1 Moersch FP, Woltman HW. Progressive fluctuating muscular rigidity and spasm (stiff-man syndrome): report of a case and some observations in 13 other cases. *Mayo Clin Proc* 1956;31:421–7.
- 2 Lorish TR, Thorsteinsson G, Howard FM Jr. Stiff-man syndrome updated. *Mayo Clin Proc* 1989;64:629–36.
- 3 Solimena M, Folli F, Denis-Donini S, *et al*. Autoantibodies to glutamic acid decarboxylase in patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. *N Engl J Med* 1988;318:1012–20.
- 4 Bosi E, Vicari A, Comi G, *et al*. Association of stiff-man syndrome and type I diabetes with islet cell and other autoantibodies. *Arch Neurol* 1988;45:246–7.
- 5 Solimena M, Folli F, Aparisi R, *et al*. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. *N Engl J Med* 1990;322:1555–60.
- 6 Baekkeskov S, Aanstoot HJ, Christgan S, *et al*. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. *Nature* 1990;347:151–6.
- 7 Bonifacio E, *et al*. Islet cell antigens in the prediction and prevention of insulin-dependent diabetes mellitus. *Ann Med* 1997;29:405–12.
- 8 Folli F, Solimena M, Cofelli R, *et al*. Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. *N Engl J Med* 1993;328:546–51.
- 9 De Camilli P, Thomas A, Cofelli R, *et al*. The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of stiff-man syndrome with breast cancer. *J Exp Med* 1993;178:2219–23.
- 10 Barker RA, Revesz T, Thom M, *et al*. A review of 23 patients affected by the stiff man syndrome. Clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome and progressive encephalomyelitis with rigidity. *J Neurol Neurosurg Psychiatry* 1998;65:000–000.
- 11 Meinck HM, Ricker K, Hulser PJ, *et al*. Stiff man syndrome: neurophysiological findings in eight patients. *J Neurol* 1995;242:134–42.